海普瑞2024中期报告

(A joint stock company incorporated in the People’s Republic of China with limited liability)（於中華人民共和國註冊成立的股份有限公司） Stock Code股份代號: 9989 Interim Report中期報告2024 Contents目錄 Corporate Information2公司資料Financial Highlights5財務摘要Management Discussion and Analysis6管理層討論與分析Corporate Governance and Other Information Disclosed22企業管治及其他披露資料Interim Condensed Consolidated Statements of Profit or Loss36中期簡明綜合損益表Interim Condensed Consolidated Statements of Comprehensive Income37中期簡明綜合全面收益表Interim Condensed Consolidated Statements of Financial Position38中期簡明綜合財務狀況表Interim Condensed Consolidated Statements of Changes in Equity40中期簡明綜合權益變動表Interim Condensed Consolidated Statements of Cash Flows42中期簡明綜合現金流量表Notes to Interim Condensed Consolidated Financial Information46中期簡明綜合財務資料附註 Corporate Information 董事會 Board of Directors 執行董事李鋰先生（董事長）李坦女士（副總經理）單宇先生（總經理）張平先生 Executive DirectorsMr. Li Li(Chairman)Ms. Li Tan(Deputy General Manager)Mr. Shan Yu(General Manager)Mr. Zhang Ping 獨立非執行董事呂川博士黃鵬先生易銘先生 Independent Non-executive DirectorsDr. Lu ChuanMr. Huang PengMr. Yi Ming 聯席公司秘書錢風奇先生陳詩婷女士(FCG, HKFCG) Joint Company Secretaries Mr. Qian FengqiMs. Chan Sze Ting(FCG, HKFCG) 授權代表錢風奇先生陳詩婷女士 Authorized RepresentativesMr. Qian FengqiMs. Chan Sze Ting 監事鄭澤輝先生（主席）唐海均女士蘇紀蘭女士（職工監事） Supervisors Mr. Zheng Zehui(Chairman)Ms. Tang HaijunMs. Su Jilan(Employee Supervisor) 戰略委員會李鋰先生（主席）李坦女士呂川博士 Strategy Committee Mr. Li Li(Chairman)Ms. Li TanDr. Lu Chuan 薪酬與考核委員會易銘先生（主席）李鋰先生黃鵬先生 Remuneration and Evaluation Committee Mr. Yi Ming(Chairman)Mr. Li LiMr. Huang Peng 審計委員會黃鵬先生（主席）呂川博士易銘先生 Audit Committee Mr. Huang Peng(Chairman)Dr. Lu ChuanMr. Yi Ming Nomination Committee 提名委員會 呂川博士（主席）李鋰先生易銘先生 Dr. Lu Chuan(Chairman)Mr. Li LiMr. Yi Ming 註冊辦事處中華人民共和國深圳市南山區朗山路21號 Registered Office No. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of China 總部及中國主要營業地點 Headquarters and Principal Place of Businessin the PRC No. 21 Langshan RoadNanshan District, ShenzhenPeople’s Republic of China 中華人民共和國深圳市南山區朗山路21號 香港主要營業地點 Principal Place of Business in Hong Kong Room 4724, 47th Floor, Sun Hung Kai Center30 Harbour Road, Wan ChaiHong Kong 香港灣仔港灣道30號新鴻基中心47樓4724室 主要往來銀行招商銀行深圳分行中國深圳市深南大道7088號招商銀行大廈 Principal Banks China Merchants Bank, Shenzhen BranchChina Merchants Bank TowerNo. 7088 Shennan BoulevardShenzhen, China 中國銀行深圳分行中國深圳市羅湖區建設路2022號 Bank of China, Shenzhen Branch2022 Jianshe Road, Luohu DistrictShenzhen, China The Hongkong and Shanghai Banking Corporation Limited1 Queen’s Road CentralHong Kong 香港上海滙豐銀行有限公司香港皇后大道中1號 Corporate Information 合規顧問 Compliance Advisor 新百利融資有限公司香港皇后大道中29號華人行20樓 Somerley Capital Limited20/F, China Building29 Queen’s Road CentralHong Kong 香港法律顧問 Hong Kong Legal Advisor 安理謝爾曼思特靈律師事務所香港中環交易廣場三座9樓 Allen Overy Shearman Sterling9/F, Three Exchange SquareCentralHong Kong 中國法律顧問 PRC Legal Advisor 北京中銀（深圳）律師事務所深圳市福田區深南大道2002號中廣核大廈北樓8層 Zhong Yin (Shenzhen) Law Firm8th Floor, North Building, China Guangdong Nuclear Power Building2002 Shennan Avenue, Futian DistrictShenzhen H股證券登記處 H Share Registrar 卓佳證券登記有限公司香港夏愨道16號遠東金融中心17樓 Tricor Investor Services Limited17/F, Far East Finance Centre16 Harcourt RoadHong Kong 股票代碼A股：002399（深圳證券交易所）H股：9989（香港聯合交易所） Stock Code A Shares: 002399 (Shenzhen Stock Exchange)H Shares: 9989 (Hong Kong Stock Exchange) 公司網站www.hepalink.com Website of the Company www.hepalink.com Financial Highlights Management Discussion and Analysis 概覽 Overview Founded in Shenzhen in 1998, Hepalink is a leading multinational pharmaceuticalcompany with A+H dual financing platform. Our main business includes theinvestment, development and commercialization of the heparin industry chain,bio-macromolecule Contract Development and Manufacturing Organization(“CDMO”) and innovative drugs. The Group’s three business segments aresynergistic and driven by unmet clinical needs; committing to providing highquality, safe and effective drugs and services for global patients to protect theirhealth. 海普瑞於一九九八年成立於深圳，是擁有A+H雙融資平台的領先跨國製藥企業，主要業務覆蓋肝素產業鏈、生物大分子合同開發和生產組織（「CDMO」）和創新藥物的投資、開發及商業化。本集團的三大板塊業務相互協同，以臨床未滿足需求為驅動，致力於為全球患者提供高質量的安全有效藥物和服務，護佑健康。 The Group’s businesses cover the manufacture and sales of pharmaceuticalproducts, development of CDMO services and innovative drugs. Our sales ofpharmaceutical products consist of (i) finished dose pharmaceutical products, whichmainly include enoxaparin sodium injection; (ii) active pharmaceutical ingredient(“API”) products, which mainly include heparin sodium API and enoxaparin sodiumAPI; and (iii) other products, which mainly include pancreatin API. In the field ofheparin industry chain, Hepalink is one of the leaders in the industry and market.The finished dose enoxaparin sodium pharmaceutical products of the Group arecurrently sold in more than 40 countries worldwide. Since the approval of finisheddose enoxaparin sodium pharmaceutical product by European Medicines Agency(“EMA”) through the Centralized Procedure (CP) in 2016, relying on